Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ZEST: niraparib versus placebo for ctDNA-positive breast cancer after definitive therapy

Phase 3 trial of niraparib versus placebo in patients with triple-negative or BRCA-mutated HER2-negative breast cancer who have ctDNA detected without radiographic recurrence. ClinicalTrials.gov lists the study as active, not recruiting, with 40 patients enrolled.

GlaxoSmithKline